Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLGW) Cash from Financing Activities (2016 - 2017)

Bone Biologics (BBLGW) has disclosed Cash from Financing Activities for 2 consecutive years, with $1.4 million as the latest value for Q3 2017.

  • Quarterly Cash from Financing Activities changed N/A to $1.4 million in Q3 2017 from the year-ago period, while the trailing twelve-month figure was $3.4 million through Dec 2017, down 50.24% year-over-year, with the annual reading at $4.7 million for FY2025, 6.26% up from the prior year.
  • Cash from Financing Activities for Q3 2017 was $1.4 million at Bone Biologics, down from $2.0 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $5.6 million in Q1 2016, with the low at $1.2 million in Q4 2016.